Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eleanor Malone

London, UK
Eleanor has been editor of Scrip Intelligence since 2014. She has more than 15 years’ experience writing specialist news and analysis for and about the biopharma industry. She holds an MA in modern languages from the University of Edinburgh. Based in London, she appears regularly on TV and radio and conference panels to discuss matters related to the industry.
Advertisement
Set Alert for Articles By Eleanor Malone

Latest From Eleanor Malone

Tazemetostat Setbacks Hit Epizyme

As drug fails in DLBCL, firm focuses on lifting partial clinical hold on other trials. A first filing in a rare sarcoma has also been pushed back.

Clinical Trials Research & Development

Hemlibra Effect Is Muted At Shire - For Now

Hemlibra has taken a bite out of Shire's FEIBA sales, but compensatory boosts in other areas of the business helped CEO Ørnskov keep the business ticking over while awaiting the finalization of Takeda's takeover.

Sales & Earnings Commercial

Good Prospects For Athenex/Almirall Following PhIII Actinic Keratosis Results

Two Phase III studies of KX2-391 to treat actinic keratosis of the face and scalp met their primary endpoint of 100% clearance. The treatment could prove more convenient than marketed therapies.

Clinical Trials Dermatology

Five Reasons Why GSK Spinning Off Consumer Is Not So Straightforward

GSK once again provided grist to the stock market rumor mill over the weekend, with reports emerging that its chairman has been talking to major shareholders about the possibility of splitting up the company. But there are reasons to doubt whether talks would lead to action any time soon.

Business Strategies Consumer

Sangamo Buys TxCell To Get In Early on CAR-Tregs In Immunology

Sangamo is to pay €72m to acquire France's TxCell, a specialist in chimeric antigen receptor-modified regulatory T-cells. It hopes ultimately to apply its zinc finger nuclease gene editing technology to develop next-generation allogeneic CAR-Treg therapies for immunological conditions.

M & A Platform Technologies

Strong Sobi With New Asset: A Takeover Target For Sanofi?

Swedish rare diseases specialist Sobi has reported strong financials and the acquisition of a rare disease candidate on the verge of US approval. Could partner Sanofi pop the question soon?

Deals M & A
See All
Advertisement
UsernamePublicRestriction

Register